Ajay Aggarwal1, Grant Lewison2, Saliha Idir3, Matthew Peters4, Carolyn Aldige5, Win Boerckel6, Peter Boyle7, Edward L Trimble8, Philip Roe9, Tariq Sethi10, Jesme Fox11, Richard Sullivan12. 1. Institute of Cancer Policy, Kings College London, London, United Kingdom. Electronic address: ajay.aggarwal@kcl.ac.uk. 2. Institute of Cancer Policy, Kings College London, London, United Kingdom; Evaluametrics Ltd., London, United Kingdom. 3. Faculty of Medicine and Health Sciences, Macquarie University, Sydney, Australia. 4. Oncology Europe, Africa, and Middle East Business Unit, Pfizer International Operations, Paris, France. 5. Prevent Cancer Foundation, Alexandria, Virginia. 6. Cancer Care, New York, New York. 7. International Prevention Research Institute, Lyon, France. 8. National Cancer Institute Center for Global Health, Bethesda, Maryland. 9. Evaluametrics Ltd., London, United Kingdom. 10. Department of Respiratory Medicine, Kings College London, London, United Kingdom. 11. Roy Castle Lung Cancer Foundation, Liverpool, United Kingdom. 12. Institute of Cancer Policy, Kings College London, London, United Kingdom.
Abstract
INTRODUCTION: Lung cancer is the leading cause of years of life lost because of cancer and is associated with the highest economic burden relative to other tumor types. Research remains at the cornerstone of achieving improved outcomes of lung cancer. We present the results of a comprehensive analysis of global lung cancer research between 2004 and 2013 (10 years). METHODS: The study used bibliometrics to undertake a quantitative analysis of research output in the 24 leading countries in cancer research internationally on the basis of articles and reviews in the Web of Science (WoS) database. RESULTS: A total of 32,161 lung cancer research articles from 2085 different journals were analyzed. Lung cancer research represented only 5.6% of overall cancer research in 2013, a 1.2% increase since 2004. The commitment to lung cancer research has fallen in most countries apart from China and shows no correlation with lung cancer burden. A review of key research types demonstrated that diagnostics, screening, and quality of life research represent 4.3%, 1.8%, and 0.3% of total lung cancer research, respectively. The leading research types were genetics (20%), systemic therapies (17%), and prognostic biomarkers (16%). Research output is increasingly basic science, with a decrease in clinical translational research output during this period. CONCLUSIONS: Our findings have established that relative to the huge health, social, and economic burden associated with lung cancer, the level of world research output lags significantly behind that of research on other malignancies. Commitment to diagnostics, screening, and quality of life research is much lower than to basic science and medical research. The study findings are expected to provide the requisite knowledge to guide future cancer research programs in lung cancer.
INTRODUCTION:Lung cancer is the leading cause of years of life lost because of cancer and is associated with the highest economic burden relative to other tumor types. Research remains at the cornerstone of achieving improved outcomes of lung cancer. We present the results of a comprehensive analysis of global lung cancer research between 2004 and 2013 (10 years). METHODS: The study used bibliometrics to undertake a quantitative analysis of research output in the 24 leading countries in cancer research internationally on the basis of articles and reviews in the Web of Science (WoS) database. RESULTS: A total of 32,161 lung cancer research articles from 2085 different journals were analyzed. Lung cancer research represented only 5.6% of overall cancer research in 2013, a 1.2% increase since 2004. The commitment to lung cancer research has fallen in most countries apart from China and shows no correlation with lung cancer burden. A review of key research types demonstrated that diagnostics, screening, and quality of life research represent 4.3%, 1.8%, and 0.3% of total lung cancer research, respectively. The leading research types were genetics (20%), systemic therapies (17%), and prognostic biomarkers (16%). Research output is increasingly basic science, with a decrease in clinical translational research output during this period. CONCLUSIONS: Our findings have established that relative to the huge health, social, and economic burden associated with lung cancer, the level of world research output lags significantly behind that of research on other malignancies. Commitment to diagnostics, screening, and quality of life research is much lower than to basic science and medical research. The study findings are expected to provide the requisite knowledge to guide future cancer research programs in lung cancer.
Authors: Grant Lewison; Ajay Aggarwal; Philip Roe; Henrik Møller; Charlotte Chamberlain; Richard Sullivan Journal: J R Soc Med Date: 2018-09-13 Impact factor: 5.344
Authors: Elizabeth M Jaffee; Chi Van Dang; David B Agus; Brian M Alexander; Kenneth C Anderson; Alan Ashworth; Anna D Barker; Roshan Bastani; Sangeeta Bhatia; Jeffrey A Bluestone; Otis Brawley; Atul J Butte; Daniel G Coit; Nancy E Davidson; Mark Davis; Ronald A DePinho; Robert B Diasio; Giulio Draetta; A Lindsay Frazier; Andrew Futreal; Sam S Gambhir; Patricia A Ganz; Levi Garraway; Stanton Gerson; Sumit Gupta; James Heath; Ruth I Hoffman; Cliff Hudis; Chanita Hughes-Halbert; Ramy Ibrahim; Hossein Jadvar; Brian Kavanagh; Rick Kittles; Quynh-Thu Le; Scott M Lippman; David Mankoff; Elaine R Mardis; Deborah K Mayer; Kelly McMasters; Neal J Meropol; Beverly Mitchell; Peter Naredi; Dean Ornish; Timothy M Pawlik; Jeffrey Peppercorn; Martin G Pomper; Derek Raghavan; Christine Ritchie; Sally W Schwarz; Richard Sullivan; Richard Wahl; Jedd D Wolchok; Sandra L Wong; Alfred Yung Journal: Lancet Oncol Date: 2017-10-31 Impact factor: 41.316
Authors: Heidi A Hamann; Elizabeth S Ver Hoeve; Lisa Carter-Harris; Jamie L Studts; Jamie S Ostroff Journal: J Thorac Oncol Date: 2018-05-23 Impact factor: 15.609
Authors: Darryl Somayaji; Amanda C Blok; Laura L Hayman; Yolanda Colson; Michael Jaklisch; Mary E Cooley Journal: Support Care Cancer Date: 2019-01-14 Impact factor: 3.603
Authors: Shubham Sharma; J Connor Wells; Wilma M Hopman; Joseph C Del Paggio; Bishal Gyawali; Nazik Hammad; Annette E Hay; Christopher M Booth Journal: Curr Oncol Date: 2021-04-13 Impact factor: 3.677